2. Academic Validation
  3. Intensity Interrogation-Based High-Sensitivity Surface Plasmon Resonance Imaging Biosensor for Apoptosis Detection in Cancer

Intensity Interrogation-Based High-Sensitivity Surface Plasmon Resonance Imaging Biosensor for Apoptosis Detection in Cancer

  • Biosensors (Basel). 2023 Oct 23;13(10):946. doi: 10.3390/bios13100946.
Xin Yuan 1,  Zhenxiao Niu 2,  Lang Liu 1,  Youjun Zeng 2,  Lin Ma 2,  Zhaogang Nie 2 3,  Zhen Tian 3,  Dongyun Kai 2,  Fangteng Zhang 2,  Guanyu Liu 2,  Siwei Li 4,  Zhengqiang Yuan 1
Affiliations

Affiliations

  • 1 School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou 510006, China.
  • 2 School of Physics & Optoelectronic Engineering, Guangdong University of Technology, Guangzhou 510006, China.
  • 3 School of Physical Science and Information Technology, Liaocheng University, Liaocheng 252059, China.
  • 4 School of Mechano-Electronic Engineering, Zhuhai City Polytechnic, Zhuhai 519000, China.
PMID: 37887139 DOI: 10.3390/bios13100946
Abstract

Intensity interrogation-based surface plasmon resonance imaging (ISPRi) sensing has a simple schematic design and is the most widely used surface plasmon resonance technology at present. In this study, we report the successful development of a novel high-sensitivity ISPRi biosensor and its application for Apoptosis detection in Cancer cells. By optimizing the excitation wavelength and excitation angle, we achieved a refractive index resolution (RIR) of 5.20 × 10-6 RIU. Importantly, the biosensor has been tested and validated for high-throughput and label-free detection of activated Caspase-3 with its specific inhibitor Z-DEVD-FMK in apoptotic cells. Therefore, this study describes a novel molecular imaging system to monitor Apoptosis in cancers for disease diagnosis and/or evaluation of therapeutic efficacy of anti-cancer drugs.

Keywords

SPRi; apoptosis; cancer; caspase-3; therapeutic efficacy assessment.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-12466
    98.0%, Caspase-3 Inhibitor